LATEST NEWS
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
GANX
What if we told you a tiny biotech team of just 25 people may have discovered a way to help reboot the broken machinery inside human cells and restore the gears that keep them running? This group is quietly backed by organizations such as the Swiss government and the Michael J. Fox Foundation. Their leadership team includes veterans who have worked across major pharmaceutical companies, global banks, and the biotechnology industry.
That company is Gain Therapeutics, trading on the NASDAQ under the ticker GANX.
A new generation of medicine is now being developed using artificial intelligence and advanced molecular modeling. While much of traditional drug development has focused on treatments that manage symptoms, one emerging company is using proprietary algorithms to identify hidden molecular “switches” on enzymes that could help restore normal cellular function.
Gain Therapeutics (nasdaq: ganx)
Technology & Innovation
What Gain Therapeutics Does
Gain Therapeutics (NASDAQ: GANX) is a clinical stage biotechnology company developing potential disease modifying therapies for neurodegenerative and rare genetic diseases using an artificial intelligence driven drug discovery platform designed to target the biological root causes of disease.
Many devastating conditions such as Parkinson’s disease are driven by proteins that misfold and stop functioning properly inside human cells.
When proteins lose their correct structure, several critical problems occur:
• Essential cellular processes begin to break down
• Toxic proteins accumulate inside cells
• Biological pathways become impaired
Over time, this damage can lead to progressive neurodegeneration.
Traditional drugs often focus on blocking symptoms by targeting a protein’s active site. While these treatments may provide temporary relief, they do not address the structural instability driving disease progression.
Gain Therapeutics is pursuing a different approach.
The company focuses on restoring the correct structure and function of damaged proteins, helping repair the biological machinery inside human cells.
AI Powered Drug Discovery Platform
At the center of Gain’s approach is its proprietary SEE-Tx platform, powered by the Magellan computational engine.
The platform integrates several advanced technologies:
• Artificial intelligence
• Structural biology
• Computational chemistry
• Physics based molecular simulations
Together these tools allow scientists to analyze proteins at atomic resolution and identify hidden allosteric binding pockets that may restore protein function.
Magellan models how proteins move and fold between functional and dysfunctional states, helping researchers locate molecular “switches” that can stabilize misfolded proteins.
Through automated virtual screening across libraries containing more than five trillion compounds, the platform identifies proprietary Structurally Targeted Allosteric Regulator candidates designed to repair protein function and restore cellular pathways.
Lead Program Targeting Parkinson’s Disease
Gain’s lead drug candidate GT-02287 is being developed for a genetically defined form of Parkinson’s disease linked to reduced glucocerebrosidase enzyme activity and lysosomal dysfunction.
The therapy is designed to:
• Restore enzyme activity
• Reduce toxic protein buildup
• Improve cellular function
Early clinical studies demonstrated statistically significant improvements in key disease biomarkers and motor function after 90 days of treatment.
Notably, 84% of patients continued into a longer extension study, highlighting ongoing interest in the therapy.
The program is advancing toward larger clinical trials expected to begin in 2026, representing a key milestone in the development of the company’s lead treatment.
Platform Potential Across Multiple Diseases
Beyond Parkinson’s disease, Gain is applying its technology platform to additional genetically defined diseases including Gaucher disease while also advancing discovery stage oncology programs targeting structurally defined proteins involved in cancer signaling.
Because the SEE-Tx platform is computationally scalable, the company believes it can expand its pipeline across multiple high unmet need areas including:
• Neurodegeneration
• Rare genetic disease
• Oncology
This platform driven strategy allows Gain to potentially build a growing portfolio of therapies based on a common discovery engine.
Research support has also come from organizations including the Michael J. Fox Foundation and the Silverstein Foundation.
Intellectual property protection for the lead program is expected through 2038.
IDENTIFYING THE OPPORTUNITY
PRICE REMAINS SUPPORTED WITHIN THIS KEY STRUCTURAL ZONE.
Price is compressing between support and resistance as the range continues to tighten!
Price Targets
Target #1: $2.20(+8.81%)
Target #2: $4.30 (+34.23%)
Target #3: $4.80 (+51.18%)
Support: ~$1.71
Introducing the Leadership Team of Gain Therapeutics
(NASDAQ: GANX)
Gene Mack
Chief Executive Officer
Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the company in April 2024 and brings more than 25 years of experience in the life sciences sector, spanning clinical research, capital markets, corporate strategy, and business development. He has previously served as CFO at Imcyse and OncoC4, and has held leadership roles at multiple development- and commercial-stage biopharmaceutical companies, raising over $350 million through IPOs and equity financings. Earlier in his career, he covered the biotechnology sector as a senior analyst at several investment banks. He holds a B.S. in Biochemistry and an M.B.A. in Finance from Fordham University.
Jonas Hannestad M.D, Ph.D.
Chief Medical Officer
Jonas Hannestad, M.D., Ph.D. serves as Chief Medical Officer of Gain Therapeutics and joined the company in March 2024. He brings more than 25 years of experience in translational research and early clinical development in central nervous system disorders. His expertise spans Parkinson’s disease, Alzheimer’s disease, and ALS, with a background in immuno-neurology and the role of systemic inflammation in brain function. Dr. Hannestad has held senior clinical leadership roles at Tranquis Therapeutics, Capacity Bio, Alkahest, Denali Therapeutics, and UCB Pharma, and previously led the Clinical Neuroscience Research Unit at the Yale School of Medicine. He holds a Ph.D. in Cell Biology from the University of Messina and an M.D. from the University of Oviedo.
Terenzio Ignoni, Pharm.D.
SVP Technical Operations
Terenzio Ignoni, Pharm.D. joined Gain Therapeutics in June 2021 as Senior Vice President of Quality and CMC. He brings more than 22 years of experience in pharmaceutical technical operations, quality systems, and regulatory CMC, with a track record of drug approvals across major global jurisdictions including the United States, Europe, Canada, Japan, Australia, and Latin America. Prior to joining Gain, he served as Vice President of Quality and Qualified Person at Jazz Pharmaceuticals, where he led product submissions, technical due diligence efforts, and regulatory inspections. Earlier in his career, he held senior quality leadership roles at Gentium, contributing to EMA drug approval and the company’s acquisition by Jazz Pharmaceuticals, as well as positions in quality control and analytical development at Biosearch Manufacturing and Zambon Group. He earned his Pharm.D. from the University of Turin, Italy.
Dr. Joanne Taylor
SVP, Research
Joanne Taylor, Ph.D. has served as a scientific advisor to Gain Therapeutics since September 2020. She brings more than 25 years of experience in the pharmaceutical industry, with deep expertise in neuroscience research and strategy. Dr. Taylor previously served as Vice President and Head of Neuroscience at Prescient Healthcare Group, where she supported portfolio, clinical, and regulatory strategies for major global pharmaceutical clients across neurology, psychiatry, ophthalmology, rare diseases, and pain. Earlier in her career, she held senior scientific leadership roles at Eisai’s London Research Laboratories, directing global teams in the discovery of novel therapeutic strategies for Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, and leading neuroscience portfolio strategy and external partnering initiatives. She earned her Ph.D. in Developmental Neuroscience from King’s College and completed postdoctoral research at ETH Zurich.
Gianluca Fuggetta
Senior Vice President, Finance
Gianluca Fuggetta has served as Senior Vice President of Finance and Principal Financial Officer of Gain Therapeutics since January 2025. He joined the company in July 2022 and has held roles of increasing responsibility, including Finance Director, Senior Finance Director, Vice President of Finance, Principal Accounting Officer (since January 2023). Prior to joining Gain Therapeutics, Mr. Fuggetta worked at PwC from September 2013 to June 2022, where he gained extensive experience in audit and assurance services across multiple international offices, including Milan, New York, and Munich, ultimately serving as Assurance Manager. Mr. Fuggetta holds a Bachelor’s degree in Economics from Università Cattolica del Sacro Cuore and a Master’s degree in Accounting from Università Bocconi.
We get our information from Earnings Alpha.
Stay Ahead. Stay Informed. Stay Profitable.
Subscribe to See What They're Watching
Sources
- https://gaintherapeutics.com/
- https://finance.yahoo.com/quote/GANX/
- GANX-February-2026-Corporate-Deck-Final4.pdf
Disclaimer
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between JRZ Capital and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker NASDAQ: GANX via digital communications beginning on April 27th 2026 and ending May 29th, 2026. Virtus Media will be paid $35,000 from Gain Therapeutics.
